Page 5 - Servier Group News Today

TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvements in complete remission rate, complete remission and complete remission

/PRNewswire/ -- Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced new data in acute...

/PRNewswire/ -- Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced new data in acute...

Servier, a global independent pharmaceutical group, announced today that the primary objective (progression free survival) of the Phase III SOLSTICE trial has not been met. SOLSTICE was designed to evaluate

Basel, Switzerland and Budapest, Hungary (PRWEB) October 12, 2021 -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical

With over 30 years of industry experience, the former Global Head of Licensing at Servier Group will spearhead LabGenius' business development, commercial strategy, and operational delivery. LabGenius

Share this article Share this article BOSTON, May 5, 2021 /PRNewswire/ -- Servier Pharmaceuticals, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) has accepted the companys supplemental New Drug Application (sNDA) for TIBSOVO (ivosidenib tablets) as a potential treatment for patients with previously treated IDH1-mutated cholangiocarcinoma. The sNDA was granted Priority Review,...

Share: Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogenes Proprietary Lymphodepletion Regimen ALLO-501A, Intended for a Potentially Pivotal Phase 2 Trial, Previously Granted FDA Fast Track Designation for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Allogene to Host Virtual CD19 Forum to Review ASCO Datasets on May ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in ... Allogene Therapeutics, Inc.April 28, 2021 GMT Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene’s Proprietary Lymphodepletion Regimen ALLO-5...

Press release content from Business Wire. The AP news staff was not involved in its creation. Servier Earns the Best Place to Work Certification in Ukraine For 2021 April 14, 2021 GMT KYIV, Ukraine--(BUSINESS WIRE)--Apr 14, 2021-- Servier Ukraine LLC, a subsidiary of Servier, a global pharmaceutical group governed by a Foundation, has been recognized as one of the best places to work for in Ukraine. The certification process consisted of an employee assessment survey conducted among Servier Ukr...